Ardelyx, Inc.

NASDAQ:ARDX

Biotechnology

Healthcare
$3.12 -1.03%

-$0.06 today

Market cap
$784.28M
Beta
0.58
P/E (TTM)
-24.5
EPS (TTM)
-$0.24
52W Low $3.49High $8.40

Volume 4.75M

Average 3.58M

ARDX EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

Ardelyx, Inc.NASDAQ: ARDX

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -$0.15, compared with -$0.17 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.24.

Context

  • EPS (Basic) grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 8 analysts of -$0.19 (+26.1%) for the fiscal year ending Dec 2026, a step up from the -52.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.15-8723.5% QoQ
Last fiscal yearDec 2025
-$0.26-52.9% YoY
LTMMar 2026
-$0.24-5.0% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.8%+17.7%+5.9 pp
1 year-52.9%+26.1%+79.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(0.26) USD
Year-over-year change
-52.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How ARDX compares with its peers on the latest reported figures

  • ARDX's LTM Mar 2026 EPS (Basic) of -$0.24 is the 3rd highest of the 5 companies compared; the peer median is -$0.39.
  • Its year-over-year change of -5.0% is the 3rd highest of 5, against a peer median of +26.1%.
ARDX Competitors Peer median
EPS (Basic) for ARDX and competitors
Company Period LTM YoY 3-year CAGR
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$0.07 +123.2%—
AKBAAkebia Therapeutics, Inc.LTM Mar 2026-$0.08 +63.2%—
ARDXArdelyx, Inc.LTM Mar 2026-$0.24 -5.0%—
DMACDiaMedica Therapeutics Inc.LTM Mar 2026-$0.71 -10.9%—
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$2.75 -4396.9%—
Peer median (excluding ARDX) -$0.39+26.1%—

Competitors are the stored peer set for ARDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.1M52.16M124.46M333.62M407.32M
Cost of Revenue1M4.12M17.8M50.56M42.6M
Gross Profit9.1M48.04M106.66M283.06M364.72M
Gross Margin90.1%92.1%85.7%84.8%89.5%
Research & Development91.14M35.2M35.54M52.32M68.47M
Selling, General & Admin72.3M76.6M134.4M258.69M337.23M
Operating Expenses163.44M111.8M169.94M311.01M405.7M
Depreciation & Amortization2.81M1.14M1.29M2.06M3.06M
EBITDA(150.85M)(60.98M)(55.35M)(16.71M)(29.17M)
EBITDA Margin-1494.0%-116.9%-44.5%-5.0%-7.2%
Operating Income(154.35M)(63.76M)(63.28M)(27.95M)(40.98M)
Operating Margin-1528.6%-122.2%-50.8%-8.4%-10.1%
Interest Income00000
Interest Expense4.5M5.07M8.87M20.09M28.4M
Other Income / Expenses(3.82M)(3.44M)(2.24M)(10.92M)(19.65M)
Income Before Tax(158.16M)(67.2M)(65.52M)(38.87M)(60.63M)
Pre-Tax Margin-1566.4%-128.8%-52.6%-11.7%-14.9%
Income Tax Expense4K8K547K266K969K
Net Income(158.17M)(67.21M)(66.07M)(39.14M)(61.6M)
Net Margin-1566.5%-128.9%-53.1%-11.7%-15.1%
EPS (Basic)(1.52)(0.42)(0.30)(0.17)(0.26)
EPS (Diluted)(1.52)(0.42)(0.30)(0.17)(0.26)
Weighted Avg Shares104.21M158.69M219.33M235.23M241.03M
Weighted Avg Shares (Diluted)104.21M158.69M219.33M235.23M241.03M

Ardelyx, Inc.

NASDAQ:ARDX

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.